Get the Stockscreener App
2.96
4.82%
-0.15
After Hours:
2.99
0.03
+1.01%
Rocket Pharmaceuticals Inc stock is traded at $2.96, with a volume of 2.10M.
It is down -4.82% in the last 24 hours and down -22.11% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.11
Open:
$3.09
24h Volume:
2.10M
Relative Volume:
0.64
Market Cap:
$323.21M
Revenue:
-
Net Income/Loss:
$-209.38M
P/E Ratio:
-1.5772
EPS:
-1.8768
Net Cash Flow:
$-179.81M
1W Performance:
-8.92%
1M Performance:
-22.11%
6M Performance:
+1.02%
1Y Performance:
-54.88%
1-Day Range:
$2.93
$3.165
1-Week Range:
$2.87
$3.40
52-Week Range:
$2.19
$6.43
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.96 | 339.59M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals (RCKT) CEO logs small stock sale to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) counsel sells small stake to cover RSU taxes - Stock Titan
Rocket Pharmaceuticals (RCKT) officer sells 384 shares to cover RSU tax withholding - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) files Form 144 to sell 55,684 shares - Stock Titan
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting - Investing.com Canada
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals - TipRanks
Rocket Pharmaceuticals (RCKT) investors approve directors, pay and option exchange - Stock Titan
Rocket Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going? - Insider Monkey
Proposed resale of 2,409 Common shares by RCKT filer (Form 144) - Stock Titan
Director resale notice — RCKT (NASDAQ: RCKT) lists 384 shares from vesting - Stock Titan
662-Share Rule 144 Notice for RCKT (NASDAQ: RCKT) - Stock Titan
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M - Insider Monkey
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Rocket Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Rocket Pharmaceuticals, Inc.Common Stock (NQ: RCKT - The Chronicle-Journal
RCKT Stock Price, Quote & Chart | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock - Investing.com UK
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock By Investing.com - Investing.com South Africa
Rocket Pharma general counsel Wilson sells $12,119 in stock - Investing.com UK
Rocket Pharma general counsel Wilson sells $12,119 in stock By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock By Investing.com - Investing.com Australia
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock - Investing.com
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax withholding - Stock Titan
Rocket Pharma (RCKT) CEO sells shares to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) insider sells 855 shares for tax withholding - Stock Titan
RCKT (NASDAQ) Rule 144: Director sales listed; 3,361 vested shares - Stock Titan
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
RCKT (NASDAQ: RCKT) files Form 144 for 855 vested shares - Stock Titan
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Lifesci Capital Analysts Raise Earnings Estimates for RCKT - MarketBeat
TradingKey - TradingKey
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock - Investing.com India
Rocket Pharmaceuticals (RCKT) insider sale covers RSU tax obligations - Stock Titan
Rocket Pharmaceuticals pursues gene therapy advances at Heart Failure 26 to accelerate early diagnosis - Traders Union
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus - The Globe and Mail
Number of shareholders of Rocket Pharmaceuticals, Inc. – GETTEX:9IP1 - TradingView
RCKT Maintained by Chardan Capital -- Price Target Remains $11 - GuruFocus
Chardan Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
RCKT SEC FilingsRocket Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results - MarketBeat
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says - Moomoo
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wilson Martin | General Counsel |
May 19 '26 |
Sale |
3.01 |
662 |
1,995 |
677,977 |
| Militello John | See Remarks |
May 19 '26 |
Sale |
3.01 |
384 |
1,157 |
89,780 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):